A Landmark Italian Study
A recent study published in The Lancet Regional Health - Europe has provided a significant piece of the puzzle. Researchers analyzed the health records of over 80,000 people with type 2 diabetes in Italy between 2004 and 2024. The primary goal was to
observe the differences between those who continued taking their GLP-1 receptor agonist (GLP-1 RA) medications and the large portion—about 60%—who stopped. Those who discontinued had typically used the medication for about a year, while those who persisted stayed on it for an average of three years. This provided a massive real-world dataset to explore the consequences of discontinuation.
A Doubled Risk for Heart Events
The study's most striking finding relates to cardiovascular health. Patients who stopped their GLP-1 treatment had approximately double the risk of suffering a non-fatal heart attack, a non-fatal stroke, or death from any cause compared to those who continued the medication. Specifically, the rate of these events was about four in every 100 people per year among those who stopped, versus roughly two in every 100 people per year for those who stayed on the drugs. The risk appeared even more pronounced for individuals with a Body Mass Index (BMI) of 30 or higher, who are considered medically obese.
The Question of Cause and Effect
It is crucial to understand the limitations of this research. As an observational study, it can identify a strong association but cannot prove that stopping the medication directly caused the increased cardiovascular risk. Experts and the study authors themselves caution that other factors could be at play. For instance, the study couldn't determine why people stopped treatment. Some may have discontinued the drugs because of gastrointestinal side effects, high costs, or because they were already in declining health, which would independently increase their risk of a cardiovascular event. The higher risk may be a sign of underlying health issues rather than a direct result of withdrawal.
What About Weight and Blood Sugar?
Interestingly, the Italian study noted that key metrics like weight, blood sugar, and blood pressure changed 'only modestly' after discontinuation, and these small changes were similar for patients who did and did not go on to have a heart attack or stroke. However, this contrasts with other studies focused specifically on weight loss, which have consistently shown significant weight regain. One 2022 study found patients regained two-thirds of the weight they lost within a year of stopping semaglutide. Other analyses suggest a full return to pre-treatment weight can occur in less than two years as appetite-suppressing effects wear off. This happens because GLP-1s quiet the 'food noise' and slow stomach emptying; when the drug is removed, hunger signals and cravings often return with force.
A Chronic Treatment for a Chronic Condition
The consensus among experts is clear: obesity and type 2 diabetes are chronic conditions that require long-term management, much like high blood pressure. GLP-1 medications are a treatment, not a cure. Their protective cardiovascular and metabolic benefits are tied to their continued use. When the medication is stopped, the biological mechanisms that drive appetite and blood sugar regulation revert toward their previous state. This is why many people experience a rebound in not just weight, but also blood pressure and cholesterol levels, which tend to drift back toward baseline within a year or so of stopping.
















